Some experts claim that reducing fluctuations throughout the day can help protect against heart disease, even for people who ...

Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track ...

Monitoring of the body’s blood sugar is essential to the treatment of diabetes. But getting effective glucose readings has ...

Glucotrack has successfully completed a first-in-human study with its continuous glucose monitor (CGM) that directly measures ...

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Trinity Biotech (TRIB) stock gains on encouraging data from a pre-pivotal clinical trial for its next-gen continuous glucose ...

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for ...

New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to ...

Smart watches, rings, and a growing array of patches are adding more functionality and being used across a growing set of ...